Zacks Investment Research upgraded shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a hold rating to a buy rating in a research note released on Tuesday. They currently have $13.00 price target on the stock.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
Other analysts have also recently issued research reports about the company. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 19th. Cantor Fitzgerald reaffirmed a buy rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Needham & Company LLC reaffirmed a buy rating and set a $25.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, ValuEngine cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $22.00.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at $11.51 on Tuesday. Aquinox Pharmaceuticals has a 52-week low of $10.02 and a 52-week high of $19.97.
Several hedge funds have recently modified their holdings of AQXP. Nexthera Capital LP acquired a new position in shares of Aquinox Pharmaceuticals in the 2nd quarter valued at about $1,276,000. University of Notre Dame DU Lac lifted its holdings in shares of Aquinox Pharmaceuticals by 11.1% in the 3rd quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock valued at $2,700,000 after buying an additional 19,066 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aquinox Pharmaceuticals by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after buying an additional 17,455 shares during the period. Citadel Advisors LLC acquired a new position in shares of Aquinox Pharmaceuticals in the 3rd quarter valued at about $194,000. Finally, Sphera Funds Management LTD. lifted its holdings in shares of Aquinox Pharmaceuticals by 21.7% in the 3rd quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after buying an additional 13,450 shares during the period. 96.25% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals (AQXP) Upgraded at Zacks Investment Research” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2018/01/13/aquinox-pharmaceuticals-aqxp-upgraded-at-zacks-investment-research.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.